Company news
Immutep Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Immutep receives 2nd IND approval for efti from US FDA
March 8, 2020
Immutep reports positive TACTI-002 data
February 18, 2020
Immutep Activities Report
January 28, 2020
Immutep expands Part C of TACTI-002 due to positive data
January 8, 2020
INSIGHT-004 clinical trial update
December 18, 2019
Immutep announces European patent grant for LAG525 antibody
November 13, 2019
Appendix 4C - quarterly
October 23, 2019
Immutep presents positive TACTI-mel melanoma trial data
October 14, 2019
Immutep receives A$2.5M R&D French Tax Incentive
October 9, 2019
Immutep expands Part A of TACTI-002 due to positive data
September 25, 2019
Immutep to receive GBP4M Milestone Payment from GSK
September 22, 2019
Japanese patent granted for LAG525 antibody
September 16, 2019
Immutep granted European patent for IMP321 in cancer
August 21, 2019
Appendix 4E & 2019 Full Year Statutory Accounts
August 20, 2019
Entitlement Offer Results & Shortfall Notification
August 1, 2019
Immutep Entitlement Offer Booklet
July 8, 2019
Immutep completes recruitment of AIPAC trial in MBC
June 24, 2019
Immutep granted Australian patent for eftilagimod alpha
June 20, 2019
Immutep completes recruitment of initial NSCLC cohort
June 13, 2019
First patient dosed in INSIGHT-004
June 5, 2019
Immutep granted European patent for eftilagimod alpha
May 22, 2019
More mature positive data for TACTI-mel trial presented
May 16, 2019
Immutep granted US patent for IMP321
March 21, 2019
IMP761 results presented at ECCO conference
March 7, 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
March 6, 2019
TACTI-mel data presented at World Immunotherapy Congress
March 5, 2019
Half Year Accounts
February 27, 2019
Immutep enters into collaboration with CYTLIMIC
January 6, 2019
Cleansing prospectus for issue of warrants
December 19, 2018
European patent granted for IMP321 & antibody combinations
November 28, 2018
Immutep granted European patent for IMP321
November 27, 2018
Positive interim TACTI-mel data presented at SITC
November 11, 2018
Immutep enters into collaboration with Pfizer & Merck KGaA
September 23, 2018
Progress towards clinical development of IMP761
September 2, 2018
Appendix 4E & 2018 Full Year Statutory Accounts
August 21, 2018
TACTI-mel Patient Recruitment Complete & Operational Update
August 6, 2018
Immutep receives IND approval from US FDA for IMP321
July 31, 2018
Immutep submits IND application with FDA
July 2, 2018
Mid-point of patient enrolment reached in AIPAC trial
June 18, 2018
Webcast slides for TACTI-mel clinical trial data
May 29, 2018
Response to ASX Price Query
May 15, 2018
Immutep raises A$6.85M through institutional placement
March 11, 2018
US patent grant for IMP701 antibody
March 5, 2018
Immutep receives A$686,704 R&D Tax Incentive
March 4, 2018
Outcome of DSMB Safety Review & Extension of TACTI-mel
February 8, 2018
Immutep receives USD1M milestone payment from EOC
February 1, 2018
European patent grant for IMP321 in cancer
November 21, 2017
Japanese Patent Grant for IMP731 Antibody
September 8, 2017
Japanese Patent Grants For IMP321 In Infectious Disease
September 5, 2017
PRR & Monash Uni receive funding grant for LAG-3 Research
August 30, 2017
Decks
The 5 newest of 112 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 30 slides · Aug 20, 2026
- Investor Presentation (February 2026)
Investor deck · 39 slides · Feb 20, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 27, 2025
- Investor Presentation (October 2025)
Investor deck · 37 slides · October 2025
- Jefferies Global Healthcare Conference 2025
Conference · 40 slides · Jun 2, 2025